"Well, the official news should come out soon." Li Zheng replied.
Guo Kezhen just walked nearby and turned his head when he heard the voice, and his eyes met Li Zheng for a moment.
Li Zheng touched his nose and nodded to Guo Kezhen.
A complicated look appeared on Guo Kezhen's face. After nodding to Li Zheng, he continued the class. However, his next class became a lot more orderly, and he no longer saw the frenzy when he just talked about gene editing technology.
When the get out of class bell rang, students, you pushed me and I pushed you, hesitantly walked to the door of the classroom.
"Professor Guo, I came here without saying hello. I'm really sorry." Li Zheng showed an embarrassed look on his face. He thought that there were so many students in a classroom that there was little chance that he should be found sitting in the corner.
Guo Kecheng showed a polite smile on his face, "It's my honor to have you come to my class, but it seems that I'm a little bit sloppy." He glanced at the dense notes on Li Zheng's opened notebook, and his eyes A hint of surprise appeared.
"You're joking, when it comes to genetics, I'm the one who gets the job done." Li Zheng paused, "I heard that you didn't seek to be the host of the Genome Project?"
He's not good at beating around the bush, and he asked outright.
Hearing this, Guo Kexuan showed an angry look on his face. If he didn't sign up, it meant that he showed weakness and gave up. Li Zheng didn't need to remind him about this.
"Professor Li, this is my own business." Guo Keao said bluntly.
Li Zheng raised his eyebrows, said "Oh", and then said casually, "I have a lecture next Wednesday."
The words that clearly didn't fit in the foreword were like thunder in Guo Keao's ears.
Next Wednesday, next Wednesday is not the first meeting of the Huaguo Genome Project preparatory group. During the meeting, the host of this Huaxia Genome Project will be selected. What does Li Zheng mean by giving a lecture next Wednesday
He didn't participate in the preparatory meeting
That means... he passed up the chance to be the host of the Genome Project.
Look at Guo Kexuan looking at him with the look of a lunatic.
Li Zheng chuckled lightly, the corner of his mouth showing a beautiful arc.
"Professor Guo, people have self-knowledge, and I have some self-knowledge. In terms of genetics, I can only be your student. I will continue to participate in promoting the Huaguo Genome Project and international cooperation, and we will cooperate in the future. Happy." He held out his hand.
Guo Keluo opened his mouth blankly, and after a long time he stretched out his hand and shook it heavily with Li Zheng.
After returning from Yanda, Li Zheng got in touch with Li Zheng's laboratory in Xiangjiang.
In the past three years, Li Zheng has been running between China and Beijing. In addition to perfecting the technology of in vitro regeneration of organs, his other experiences have been invested in the development of a human papillomavirus vaccine.
Many people may not know about the human papilloma virus, but the HPV vaccine, female compatriots in later generations should understand it as soon as they hear it.
This is a vaccine that can prevent cervical cancer. Many people later call it the first vaccine that can prevent cancer. In fact, this claim is exaggerating. In Li Zheng's view, the vaccine was approved by the FDA in 1986. The hepatitis B vaccine is the first vaccine that can prevent cancer in the actual sense. Although it is clearly stated to prevent acute hepatitis when it is used as a drug, you have to admit that it does greatly reduce the incidence of liver cancer.
In the late 1980s and early 1990s, German biologist Hausen had published the view that HPV is carcinogenic. However, even though Hausen's group discovered HPV16 and HPV18 and their carcinogenic mechanisms, pharmaceutical companies were generally skeptical. And after the publication of Hausen's paper, a series of various reports came one after another, all refuting the carcinogenicity of HPV.
After erlotinib entered the FDA approval process, Li Zheng met the German biologist at an international anti-tumor conference, and he was working to persuade international pharmaceutical companies to develop an HPV vaccine.
GlaxoSmithKline and Merck, who later produced HPV vaccines, were all interested in HPV vaccines at this time.
"Even now, biology can't fully explain the causal relationship between hepatitis B virus and liver cancer. He wants to repeat the miracle of hepatitis B virus. He is too impatient." Kent used a very euphemistic word.
Li Zheng raised his eyebrows, "But you have to admit that the hepatitis B vaccine has indeed made a great contribution to the history of mankind's fight against diseases."
Kent was stunned for a moment, then laughed, "What, Li, are you interested in this HPV vaccine?"
Li Zheng smiled, "If I say I'm interested."
Kent looked at Li Zheng for a long time, made sure he didn't lie any more, and shrugged, "Then I might be able to submit an evaluation report to the audit team."
Submitting an evaluation report to the audit team is a very conservative statement. At the speed of the Merck audit team, it may not be possible to complete the audit of a project in two or three years. Only some projects that are tasteless and unfortunate to discard, pharmaceutical companies can It will be submitted to the audit team for review. This already shows Kent's attitude towards this project.
The carcinogenicity of HPV will be gradually recognized by the world biological circle after 1991. The biological circle recognizes it, pharmaceutical companies attach great importance to it, and then major research institutions take the drug to the market. It took a full 16 years in the last life.
Li Zheng also made some achievements in vaccinology in his previous life. The studio under his name promoted the birth of the domestic HPV virus vaccine. And before his sudden death, the HIV vaccine he presided over also showed good biological tolerance in biological tests, and the effectiveness reached more than 50%. In other words, give him another year or two, and the HIV virus that the people of the world have heard about may be able to end in his hands.
So Li Zheng found Haosen and asked him for cooperation. For Haosen at this moment, it is very pleasing that someone is willing to believe his views and invest a lot of money in vaccine development according to his views. .
What's more, Li Zheng did not put forward any domineering requirements in the cooperation agreement. Haosen can continue to persuade other pharmaceutical companies to develop vaccines while Li Zheng's laboratory is developing drugs, which completely relieves Haosen from worries. .
So the German old man signed a cooperation agreement with Li Zheng very happily.
As a result, Li Zheng's laboratory began a three-year anti-cancer vaccine research.
Up to now, the HPV virus vaccine of Li Zheng's laboratory has been able to defend against a variety of high-risk HPV types including 16 and 18 types. 70% of cervical cancers are caused by two subtypes of HPV16 and HPV18 viruses. In other words, the HPV vaccine developed by Li Zheng's laboratory can theoretically prevent 70% of cervical cancers.
It's just that vaccine clinical trials have always been a huge difficulty in drug development, and Li Zheng has been very busy with it recently. He intends to use this as the first world-class drug clinical trial after the establishment of the domestic drug clinical trial standard, but it is obvious that the risk assessment of this drug clinical practice is too high in China. Li Zheng talked with the drug administration department several times and got All are answers that require further research.
"Li Zheng, Professor Hausen hopes that the drug can enter the human clinical stage as soon as possible. What he means is that if Huaguo fails, he can find a way in Germany." Zheng Lingling said.
In three years, it was enough for a young lady who just graduated to become a qualified professional woman.
A drug patent can support a company, not to mention that Li Zheng's laboratory has multiple high-value drug patents, which is enough to make Zhenzhe Biotechnology smooth sailing in the pharmaceutical industry, and it has a good reputation with major international pharmaceutical companies. Relationship.
The only thing missing is a work that allows the world to know Zhenzhe, so Zheng Lingling is very interested in this project.
Li Zheng rubbed his temples.
"Let me try again." Zhenzhen needs world recognition, and so does China's pharmaceutical industry.
Zheng Lingling sighed, "Okay, you are the boss, but Li Zheng, Zhenzhe is also your industry, the development of HPV has almost emptied all the patent funds you have accumulated, and the sooner you make money, the sooner you will pay back, I believe you I know the truth." The current Mr. Zheng is not the little girl from before, she would often make Li Zheng speechless.
"Okay okay, one last time. I promise it's the last time."
**
On April 10, 1990, the official launch of the Huaguo Human Genome Project was announced in the Great Hall of the People. Guo Keao, the vice president of the Department of Biology of Yanda University, the honorary president of the Huaguo Biogenetics Association, and a Huaguo biologist, was appointed as this project. host of the program.
There was thunderous applause in the synagogue.
"That kid Li Zheng really didn't come?" Zhao Depei clapped his hands and set his eyes on the vacant seat in the front row.
"He should be taking classes at Jinjiang University now." Tian Lao smiled and said, turning his head to the side.
"A literature and history college, what class should Li Zheng be invited to teach? Why, they have the intention to move towards a comprehensive college?"
"Who knows. But Xiao Zhao, how much do you know about the project Li Zheng is working on?" Tian Xiangjun was a little bit windy about the so-called small project Li Zheng was working on, but he was skeptical about it.
"I don't know the biology very well. If he really developed the HPV virus and cervical cancer, it would be the first anti-cancer vaccine in history. This title can still be worn."
"The carcinogenicity of Hansoh HPV has been criticized internationally, and the clinical vaccine is still a cancer vaccine, which puts a lot of pressure on the clinic. No wonder they are unwilling to do so."
"Why are they unwilling? They want results and don't want to take risks. Old Wang supports it, but there are too many people in the department who oppose it. It's hard to support it alone."
"Officials are different from our research. They are prudent and creative. They will choose to pursue the latter while ensuring the former."